Monkeys infected with novel coronavirus developed short-term immunity

Published Fri, Jul 3, 2020 · 12:37 AM

[WASHINGTON] Test monkeys infected with the novel coronavirus responsible for the Covid-19 pandemic were protected from reinfection for up to 28 days later, a Chinese study out Thursday in the journal Science said.

While the monkeys displayed initial immunity, it's unclear how long such immunity will last in humans - it will be necessary to wait months, or even years, to know if the millions of people infected at the start of the pandemic are protected from re-infection.

Scientists from Peking Union Medical College performed an experiment on rhesus macaques, often used because of their similarities to humans, to find out if they have a short-term immunity to the virus.

Six rhesus macaques were infected in their trachea with a dose of the SARS-CoV-2 virus. They developed mild to moderate symptoms, and took about two weeks to recover.

Twenty-eight days after the first infection, four of the six monkeys received another dose of virus, but this time, despite a brief rise in temperature, they showed no sign of reinfection, the study authors wrote.

By taking frequent samples the researchers discovered that the peak viral load was reached three days after the monkeys were infected.

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

VIEW ALL

The monkeys showed a stronger immune response after the first infection, producing more so-called neutralising antibodies which may have protected them against short-term reinfection, the scientists wrote.

More experiments are needed to see how long this immune defence remains, the authors said.

AFP

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

International

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here